Rebif (Merck Serono) is EU approved for Early Multiple Sclerosis

The European Commission has approved an extended indication for Rebif (interferon beta-1a) from Merck Serono, allowing its use in patients with early Multiple Sclerosis, in line with an earlier recommendation by the CHMP. It recommended that 44 micrograms of Rebif three times weekly should be given to patients who have experienced a single demyelinating event, an early sign of Multiple Sclerosis, and who are at high risk of developing the disease.